Pacific Biosciences Of California (PACB) Net Cash Flow Growth (1y) (2011 - 2026)
Pacific Biosciences Of California (PACB) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.46 Bn | 193.86 Bn | 7.27 Bn | -562.77% |
| 2 | Stryker | 127.41 Bn | 123.93 Bn | 4.50 Bn | 2,827.78% |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn | 10.50% |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn | -395.56% |
| 5 | Edwards Lifesciences | 51.95 Bn | 47.69 Bn | 1.35 Bn | 168.38% |
| 6 | Dexcom | 34.30 Bn | 32.35 Bn | 830.00 Mn | -103.49% |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | -114.85% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.02 Bn | 4.55 Bn | -215.59% |
| 9 | Steris | 23.04 Bn | 22.55 Bn | 684.20 Mn | -54.17% |
| 10 | Pacific Biosciences Of California | 394.53 Mn | 157.66 Mn | 12.64 Mn | 215.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 215.85% |
| Mar 31, 2026 | -335.73% |
| Dec 31, 2025 | 130.78% |
| Sep 30, 2025 | 107.71% |
| Jun 30, 2025 | -118.26% |
| Mar 31, 2025 | 103.04% |
| Dec 31, 2024 | 89.01% |
| Sep 30, 2024 | -112.24% |
| Jun 30, 2024 | 115.46% |
| Mar 31, 2024 | -459.25% |
| Dec 31, 2023 | -1,096.02% |
| Sep 30, 2023 | 3,033.48% |
| Jun 30, 2023 | -20.48% |
| Mar 31, 2023 | 190.50% |
| Dec 31, 2022 | -41.60% |
| Jun 30, 2022 | 74.58% |
| Mar 31, 2022 | -103.73% |
| Dec 31, 2021 | 169.60% |
| Jun 30, 2021 | -1,720.29% |
| Mar 31, 2021 | 2,068.44% |